| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.097 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | -0.091 | 0.1 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.1 |